In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined Alzheimer’s Research UK in 2013 and has overseen significant growth in income in recent years, which has ...

Drugs targeting amyloid plaques have failed to show efficacy in clinical trials. A new approach is needed to tackle AD ...

Why the once-stigmatized treatment is back for women under 60.

Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...

When someone with dementia loses their ability to have empathy, caring for them can become isolating and fraught, research ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...